rs10455872 — LPA

Intronic variant strongly associated with elevated lipoprotein(a) levels and significantly increased risk of coronary artery disease

See your personal result for LPA

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Lp(a) Risk Variant — A Major Genetic Determinant of Heart Disease

The LPA gene encodes apolipoprotein(a)11 apolipoprotein(a)
the protein component that distinguishes lipoprotein(a) from regular LDL cholesterol, and rs10455872 is one of the most powerful genetic predictors of cardiovascular disease identified to date. Located in intron 25 of the LPA gene22 intron 25 of the LPA gene
a non-coding region that influences gene expression through unknown mechanisms, this variant emerged as a genome-wide association study hit with extraordinary statistical significance33 genome-wide association study hit with extraordinary statistical significance
P = 3.4×10⁻¹⁵ for coronary disease.

Lipoprotein(a), or Lp(a), is an LDL-like particle with an additional apolipoprotein(a) component44 LDL-like particle with an additional apolipoprotein(a) component
making it structurally unique among lipoproteins. Unlike LDL cholesterol, which responds robustly to diet and statin therapy, Lp(a) levels are 70-90% genetically determined55 70-90% genetically determined
largely controlled by variation at the LPA locus on chromosome 6q26-27. The G allele at rs10455872 is associated with smaller apolipoprotein(a) isoforms and significantly elevated Lp(a) concentrations66 smaller apolipoprotein(a) isoforms and significantly elevated Lp(a) concentrations
smaller isoforms are more atherogenic and thrombogenic.

The Mechanism

The rs10455872 variant sits within an intron and does not change the protein sequence, suggesting it affects gene expression or RNA processing77 gene expression or RNA processing
possibly through regulatory elements or chromatin structure. The G allele correlates with reduced copy number of the kringle IV type 2 (KIV-2) repeats88 reduced copy number of the kringle IV type 2 (KIV-2) repeats
resulting in smaller apolipoprotein(a) isoforms that are more efficiently synthesized and catabolized more slowly.

Elevated Lp(a) contributes to cardiovascular disease through multiple mechanisms99 multiple mechanisms
atherosclerosis, inflammation, and thrombosis: it delivers cholesterol to arterial walls like LDL, carries pro-inflammatory oxidized phospholipids1010 pro-inflammatory oxidized phospholipids
bound to the kringle IV domains of apolipoprotein(a), and has anti-fibrinolytic effects1111 anti-fibrinolytic effects
its structural similarity to plasminogen allows it to compete with plasminogen and impair clot breakdown.

The Evidence

The association between rs10455872 and cardiovascular disease is among the strongest and most replicated in human genetics. Clarke et al. in the landmark 2009 NEJM study1212 Clarke et al. in the landmark 2009 NEJM study
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease. N Engl J Med 2009;361:2518-28 identified rs10455872 with an [odds ratio of 1.70 for coronary disease | 95% CI 1.49-1.95, one of the highest effect sizes for common variants]. When combined with another LPA variant (rs3798220), the odds ratio reached 2.57 for individuals with two or more risk alleles1313 odds ratio reached 2.57 for individuals with two or more risk alleles
indicating a gene-dose effect.

A Brazilian study of 1,394 patients undergoing coronary angiography1414 Brazilian study of 1,394 patients undergoing coronary angiography
validating the association in a different ethnic population confirmed the G allele doubled the odds of coronary lesions1515 G allele doubled the odds of coronary lesions
OR 2.02, and correlated with lesion severity scores.

A 2025 meta-analysis of 55,647 participants1616 2025 meta-analysis of 55,647 participants
including 12,406 CHD cases and 17,321 controls for rs10455872 found the G allele associated with 1.6-fold increased coronary heart disease risk under multiple genetic models1717 1.6-fold increased coronary heart disease risk under multiple genetic models
allelic OR 1.607, dominant OR 1.751.

The FOURIER trial analysis1818 FOURIER trial analysis
including 25,096 patients with established cardiovascular disease demonstrated that [patients with Lp(a) in the highest quartile had significantly higher coronary event rates | and derived greater absolute benefit from PCSK9 inhibition], providing evidence that lowering Lp(a) reduces cardiovascular risk.

Practical Implications

If you carry one or two G alleles, you have genetically elevated Lp(a) — a risk factor that operates independently of LDL cholesterol1919 independently of LDL cholesterol
meaning traditional cholesterol control may not eliminate your residual cardiovascular risk. The first step is measuring your serum Lp(a) level2020 measuring your serum Lp(a) level
a single measurement is sufficient since Lp(a) is highly stable over time. Current guidelines recommend screening Lp(a) once in all adults2121 screening Lp(a) once in all adults
particularly those with premature cardiovascular disease, family history of heart disease, or recurrent events despite optimal LDL control.

Standard statins do not lower Lp(a)2222 Standard statins do not lower Lp(a)
and may modestly increase it in some individuals, though statins remain essential for LDL lowering. Niacin can reduce Lp(a) by 20-30%2323 Niacin can reduce Lp(a) by 20-30%
but has not shown cardiovascular benefit in outcome trials. The most effective currently available therapies are PCSK9 inhibitors (evolocumab, alirocumab)2424 PCSK9 inhibitors (evolocumab, alirocumab)
which lower Lp(a) by 20-27% in addition to dramatically lowering LDL, and lipoprotein apheresis2525 lipoprotein apheresis
which can reduce Lp(a) by 60-75% but requires twice-monthly extracorporeal treatments.

New RNA-based therapies specifically targeting apolipoprotein(a)2626 New RNA-based therapies specifically targeting apolipoprotein(a)
including antisense oligonucleotides and siRNA are in late-stage development.

Beyond medication, intensive LDL lowering takes on added importance2727 intensive LDL lowering takes on added importance
because the cardiovascular risk from Lp(a) and LDL are additive. Anti-inflammatory interventions may also help2828 Anti-inflammatory interventions may also help
since Lp(a) acts partly through inflammatory pathways. Lifestyle measures—regular aerobic exercise, Mediterranean diet, smoking cessation2929 regular aerobic exercise, Mediterranean diet, smoking cessation
the foundations of cardiovascular prevention—remain crucial, and aggressive management of all modifiable risk factors3030 aggressive management of all modifiable risk factors
hypertension, diabetes, obesity becomes even more important when genetic risk is elevated.

Interactions

The rs10455872 variant interacts with rs37982203131 rs3798220
another LPA variant in the kringle IV domain, and the two form three major haplotypes with combined effects on Lp(a) levels and cardiovascular risk3232 three major haplotypes with combined effects on Lp(a) levels and cardiovascular risk
combining both variants into a single genotype score predicts risk more accurately than either alone. Individuals carrying variant alleles at both positions face dramatically elevated risk3333 variant alleles at both positions face dramatically elevated risk
OR 2.57 compared to non-carriers.

The cardiovascular risk conferred by elevated Lp(a) is modified by concurrent LDL cholesterol levels3434 modified by concurrent LDL cholesterol levels
risk attenuates somewhat when LDL is very well controlled, but does not disappear. Understanding the combined genetic burden across the LPA locus provides the most complete picture of inherited risk.

Genotype Interpretations

What each possible genotype means for this variant.

AA Normal Lp(a) Genetic Risk Normal

Typical genetic contribution to lipoprotein(a) levels and cardiovascular risk

You carry two copies of the common A allele at rs10455872, meaning you have no genetic predisposition for elevated lipoprotein(a) from this variant. About 87% of individuals of European ancestry share your genotype. Your Lp(a) levels are determined by other genetic factors and environmental influences, and are likely in the lower range on average. While you lack this specific genetic risk factor, Lp(a) levels can still vary, and measuring your actual Lp(a) level remains valuable for comprehensive cardiovascular risk assessment.

AG Moderately Elevated Lp(a) Risk Intermediate

One copy of the risk allele moderately increases lipoprotein(a) levels and cardiovascular risk

Heterozygosity at rs10455872 places you at intermediate genetic risk for elevated Lp(a). Studies show that AG carriers have odds ratios for coronary disease of approximately 1.70-1.75 | representing 70-75% increased relative risk, though absolute risk depends on your total cardiovascular risk profile. Your single G allele is associated with smaller apolipoprotein(a) isoforms | fewer kringle IV repeats that are more efficiently produced and metabolized more slowly. This genetic architecture typically results in Lp(a) levels in the 30-100 mg/dL range, though measurement is essential to know your actual level. The risk appears additive with other cardiovascular risk factors | combining with LDL cholesterol, hypertension, and diabetes. Importantly, family members may also carry this variant | first-degree relatives have a 50% chance of inheriting the G allele from you, suggesting family screening may be valuable.

GG High Lp(a) Genetic Risk High Risk

Two copies of the risk allele substantially elevate lipoprotein(a) levels and cardiovascular risk

As a GG homozygote, you have the highest genetic burden for elevated Lp(a) at this position. Studies show that individuals with two risk alleles at LPA variants have odds ratios for coronary disease of 2.57, with some individuals experiencing premature cardiovascular events in their 30s-40s despite otherwise favorable risk profiles. Your dual G alleles produce very small apolipoprotein(a) isoforms | the fewest kringle IV repeats, which are synthesized most efficiently and catabolized most slowly, leading to persistently high Lp(a) concentrations. Most GG carriers have Lp(a) levels >100 mg/dL, with many exceeding 200 mg/dL—levels associated with 70% increased cardiovascular disease risk compared to those with levels <5 mg/dL.

Your cardiovascular risk cannot be adequately controlled by standard statin therapy alone, as statins do not lower Lp(a) and may modestly raise it | requiring additional interventions beyond LDL lowering. The mechanism of your elevated risk is multifactorial: atherogenic cholesterol delivery to arterial walls, pro-inflammatory oxidized phospholipids carried by Lp(a), anti-fibrinolytic effects impairing clot breakdown | making both plaque formation and thrombotic events more likely. Evidence from Mendelian randomization studies | the strongest design for inferring causality definitively establishes that your elevated Lp(a) directly causes cardiovascular disease, not merely as a marker but as an active pathologic agent.

Importantly, all first-degree relatives have a 50% chance of carrying at least one G allele | and 25% chance of being fellow GG homozygotes, making family screening and cascade testing essential. Early identification and intervention in relatives can prevent premature cardiovascular events.